ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IRTC
NEW YORK, March 9, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023, both dates inclusive (the “Class Period”), of the important Apri
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Late-breaking platform presentation showed that BIMZELX® (bimekizumab-bkzx) rapidly achieved and maintained high rates of clinical and health-related quality-of-life responses through four years; six out of ten patients achieved complete skin clearance at Year 4Responder-analyses demonstrated that
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting SAN DIEGO, March 9,
Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study
– Potent topical MPC inhibitor, based on discovery of a metabolic switch, reawakens dormant hair follicle stem cells to stimulate hair growth – PP405 demonstrates statistically significant activation of Ki67 in the hair follicle, a well-established marker of stem cell proliferation LOS
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif., March 9, 202
Statement: Assistance on the Way for Low-Income Older Americans
ARLINGTON, Va., March 9, 2024 /PRNewswire/ — The following is a statement from Ramsey Alwin, President and CEO of the National Council on Aging (NCOA), on yesterday’s passage of the federal appropriations package in the Senate: “We applaud Congress for funding critical assistance f
U.S. Postal Service Pays Homage to Heroes of the Underground Railroad With New Forever Stamps
CHURCH CREEK, Md., March 9, 2024 /PRNewswire/ — The U.S. Postal Service today celebrated the ingenuity, bravery, and resilience of 10 courageous men and women who helped guide enslaved people to freedom via the Underground Railroad, a network of secret routes and safehouses in use before the
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hut 8 Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HUT
NEW YORK, March 9, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hut 8 Corp. (NASDAQ: HUT) between November 9, 2023 and January 18, 2024, both dates inclusive (the “Class Period”), of the important April 8, 2024 lea
Media Advisory – Governor General to support Canadian athletes at the Arctic Winter Games
OTTAWA, ON, March 9, 2024 /CNW/ – At the request of the Right Honourable Justin Trudeau, Prime Minister of Canada, Her Excellency the Right Honourable Mary Simon, Governor General of Canada, will travel to Alaska, from March 9 to 12, 2024, to attend the Arctic Winter Games. Her ExcellencyR
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II Investors to Secure Counsel Before Important Deadline in Securities Class Action – KIND, KVSB
NEW YORK, March 9, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND) (NASDAQ: KVSB) between July 6, 2021 and November 8, 2022, both dates inclu
